Portfolio Companies

The Cancer Focus Fund’s portfolio companies are driven to revolutionize the industry of cancer therapies and provide patients with better outcomes in the process.

Mereo BioPharma (NASDAQ: MREO) is a publicly traded San Diego and London-based biotech developing and commercializing new therapies for oncology and rare disease.

Kahr Logo

KAHR is a private clinical stage company based in Israel developing innovative immune-recruitment cancer drugs that activate immune responses by converting cancer camouflage into beacons for the immune system to attack.

Nectin Therapeutics is a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments.

ISA Pharmaceuticals is a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases.

ImmunoGenesis is an immuno-oncology biopharmaceutical company re-envisioning “cold” tumor treatment.

March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers.

Eisbach Bio is a clinical-stage biotechnology company focused on precision oncology, aiming to disrupt tumor growth by targeting genetic vulnerabilities.